133 related articles for article (PubMed ID: 2149024)
1. Comparison of mass spectrometry and radioimmunoassay to measure medroxyprogesterone acetate in patients with endometrial cancer.
Kärkkäinen J; Vesterinen E; Stenman UH; Adlercreutz H; Nieminen U; Widholm O
Eur J Cancer; 1990; 26(9):975-7. PubMed ID: 2149024
[TBL] [Abstract][Full Text] [Related]
2. Specific and sensitive determination of medroxyprogesterone acetate in human serum by gas chromatography-mass spectrometry.
Dikkeschei LD; van Veelen H; Nagel GT; Willemse PH; Wolthers BG
J Chromatogr; 1985 Nov; 345(1):1-10. PubMed ID: 2935550
[TBL] [Abstract][Full Text] [Related]
3. Plasma medroxyprogesterone acetate levels following intramuscular or oral administration in patients with endometrial adenocarcinoma.
Laatikainen T; Nieminen U; Adlercreutz H
Acta Obstet Gynecol Scand; 1979; 58(1):95-9. PubMed ID: 419965
[TBL] [Abstract][Full Text] [Related]
4. [Progesterone receptors in endometrial carcinoma and their response to medroxyprogesterone acetate].
Feng YJ; Zhang XY
Zhonghua Fu Chan Ke Za Zhi; 1989 May; 24(3):153-5, 189. PubMed ID: 2530067
[TBL] [Abstract][Full Text] [Related]
5. [The medroxyprogesterone acetate serum level following various medroxyprogesterone acetate dose schedules in gynecologic oncology].
Husslein P; Egarter C; Eppel W; Salzer H; Spona J
Zentralbl Gynakol; 1988; 110(20):1277-82. PubMed ID: 2977043
[TBL] [Abstract][Full Text] [Related]
6. [Adjuvant hormone therapy in endometrial carcinoma: medroxyprogesterone acetate versus tamoxifen-medroxyprogesterone acetate sequential therapy].
Vavra N; Salzer H; Sevelda P; Breitenecker G; Czerwenka K; Kucera H
Gynakol Rundsch; 1990; 30(3):133-43. PubMed ID: 2147161
[TBL] [Abstract][Full Text] [Related]
7. Medroxyprogesterone acetate does not perturb the profile of steroid metabolites in urine during pregnancy.
Yovich JL; Willcox DL; Wilkinson SP; Poletti VM; Hähnel R
J Endocrinol; 1985 Mar; 104(3):453-9. PubMed ID: 3156203
[TBL] [Abstract][Full Text] [Related]
8. Medroxyprogesterone acetate: variation in serum concentrations achieved with three commercially available preparations.
Stockdale AD; Chapman D; Mould GP; Rostom AY
Cancer Treat Rep; 1987 Sep; 71(9):813-5. PubMed ID: 2957052
[TBL] [Abstract][Full Text] [Related]
9. [A case of marked effectiveness using medroxyprogesterone acetate (MPA) in lung metastases of cancer of the uterine body].
Takeda M; Kubo K; Fukushima M; Hirayama J; Sekiguchi M
Gan To Kagaku Ryoho; 1990 Oct; 17(10):2113-7. PubMed ID: 2145808
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen and medroxyprogesterone therapy for advanced endometrial carcinoma.
Rendina GM; Donadio C; Fabri M; Mazzoni P; Nazzicone P
Eur J Obstet Gynecol Reprod Biol; 1984 Jun; 17(4):285-91. PubMed ID: 6235140
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and metabolism of medroxyprogesterone acetate in patients with advanced breast cancer.
Utaaker E; Lundgren S; Kvinnsland S; Aakvaag A
J Steroid Biochem; 1988 Oct; 31(4A):437-41. PubMed ID: 2971841
[TBL] [Abstract][Full Text] [Related]
12. The plasma concentration of medroxyprogesterone acetate and ovarian function during treatment with medroxyprogesterone acetate in 5 and 10 mg doses.
Wikström A; Green B; Johansson ED
Acta Obstet Gynecol Scand; 1984; 63(2):163-8. PubMed ID: 6233840
[TBL] [Abstract][Full Text] [Related]
13. [Oral high doses of medroxyprogesterone acetate (MPA) in the treatment of advanced phases of breast and endometrial cancer].
Bernardo-Strada MR; Imparato E; Aspesi G; Pavesi L; Robustelli Della Cuna G
Minerva Med; 1980 Nov; 71(44):3241-6. PubMed ID: 7454090
[TBL] [Abstract][Full Text] [Related]
14. A comparison of medroxyprogesterone serum concentrations by the oral or intramuscular route in patients with persistent or recurrent endometrial carcinoma.
Sall S; DiSaia P; Morrow CP; Mortel R; Prem K; Thigpen T; Creasman W
Am J Obstet Gynecol; 1979 Nov; 135(5):647-50. PubMed ID: 507117
[TBL] [Abstract][Full Text] [Related]
15. High-dose depot-medroxyprogesterone acetate--effects on the fatty acid composition of serum lecithin and cholesterol ester.
Enk L; Crona N; Friberg LG; Samsioe G; Silfverstolpe G
Gynecol Oncol; 1985 Nov; 22(3):317-23. PubMed ID: 2933308
[TBL] [Abstract][Full Text] [Related]
16. Specific and sensitive quantitation of medroxyprogesterone acetate in human serum by gas chromatography-mass spectrometry.
Järvinen T; Keinonen T; Auriola S; Peura P; Hirvonen E; Palva E
J Chromatogr; 1989 Oct; 495():13-20. PubMed ID: 2533215
[TBL] [Abstract][Full Text] [Related]
17. Bioavailability of medroxyprogesterone acetate from three oral dosage formulations.
Stalker DJ; Welshman IR; Pollock SR
Clin Ther; 1992; 14(4):544-52. PubMed ID: 1388093
[TBL] [Abstract][Full Text] [Related]
18. [Growth of endometrial cancer and hormone].
Kanoh H; Hosono T; Matsui Y; Okudaira Y
Gan To Kagaku Ryoho; 1989 Dec; 16(12):3696-703. PubMed ID: 2531993
[TBL] [Abstract][Full Text] [Related]
19. Lack of correlations between plasma concentration of medroxyprogesterone acetate, hypothalamic-pituitary function, and tumour response in patients with advanced breast cancer.
Hedley DW; Christie M; Weatherby RP; Caterson ID
Cancer Chemother Pharmacol; 1985; 14(2):112-5. PubMed ID: 3156002
[TBL] [Abstract][Full Text] [Related]
20. [High-dosage medroxyprogesterone acetate treatment in advanced prostatic cancer].
Flamm J; Spona J
Wien Klin Wochenschr; 1987 Oct; 99(19):682-6. PubMed ID: 2961131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
